Medicenna Therapeutics Corp. MDNA.TO Stock
Medicenna Therapeutics Corp. Price Chart
Medicenna Therapeutics Corp. MDNA.TO Financial and Trading Overview
| Medicenna Therapeutics Corp. stock price | 1.96 CAD |
| Previous Close | 0.82 CAD |
| Open | 0.83 CAD |
| Bid | 0.77 CAD x N/A |
| Ask | 0.81 CAD x N/A |
| Day's Range | 0.78 - 0.83 CAD |
| 52 Week Range | 0.54 - 2.38 CAD |
| Volume | 17.75K CAD |
| Avg. Volume | 15.87K CAD |
| Market Cap | 54.32M CAD |
| Beta (5Y Monthly) | 0.583453 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.23 CAD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.85 CAD |
MDNA.TO Valuation Measures
| Enterprise Value | 20.95M CAD |
| Trailing P/E | N/A |
| Forward P/E | -2.2941175 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.63522 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.225 |
Trading Information
Medicenna Therapeutics Corp. Stock Price History
| Beta (5Y Monthly) | 0.583453 |
| 52-Week Change | -24.27% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.38 CAD |
| 52 Week Low | 0.54 CAD |
| 50-Day Moving Average | 0.85 CAD |
| 200-Day Moving Average | 0.88 CAD |
MDNA.TO Share Statistics
| Avg. Volume (3 month) | 15.87K CAD |
| Avg. Daily Volume (10-Days) | 12.18K CAD |
| Shares Outstanding | 69.64M |
| Float | 48.74M |
| Short Ratio | 4.76 |
| % Held by Insiders | 23.65% |
| % Held by Institutions | 14.00% |
| Shares Short | 100.29K |
| Short % of Float | 0.20% |
| Short % of Shares Outstanding | 0.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | March 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -33.27% |
| Return on Equity (ttm) | -32.98% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -17100000 CAD |
| Net Income Avi to Common (ttm) | -9398000 CAD |
| Diluted EPS (ttm) | -0.16 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 36.15M CAD |
| Total Cash Per Share (mrq) | 0.52 CAD |
| Total Debt (mrq) | 0 CAD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 7.701 |
| Book Value Per Share (mrq) | 0.477 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -13263000 CAD |
| Levered Free Cash Flow (ttm) | -5984375 CAD |
Profile of Medicenna Therapeutics Corp.
| Country | Canada |
| State | ON |
| City | Toronto |
| Address | 2 Bloor Street West |
| ZIP | M4W 3E2 |
| Phone | N/A |
| Website | https://www.medicenna.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 18 |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Q&A For Medicenna Therapeutics Corp. Stock
What is a current MDNA.TO stock price?
Medicenna Therapeutics Corp. MDNA.TO stock price today per share is 1.96 CAD.
How to purchase Medicenna Therapeutics Corp. stock?
You can buy MDNA.TO shares on the Toronto exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Medicenna Therapeutics Corp.?
The stock symbol or ticker of Medicenna Therapeutics Corp. is MDNA.TO.
Which industry does the Medicenna Therapeutics Corp. company belong to?
The Medicenna Therapeutics Corp. industry is Biotechnology.
How many shares does Medicenna Therapeutics Corp. have in circulation?
The max supply of Medicenna Therapeutics Corp. shares is 69.64M.
What is Medicenna Therapeutics Corp. Price to Earnings Ratio (PE Ratio)?
Medicenna Therapeutics Corp. PE Ratio is now.
What was Medicenna Therapeutics Corp. earnings per share over the trailing 12 months (TTM)?
Medicenna Therapeutics Corp. EPS is -0.23 CAD over the trailing 12 months.
Which sector does the Medicenna Therapeutics Corp. company belong to?
The Medicenna Therapeutics Corp. sector is Healthcare.